AZ buys oral PCSK9 cholesterol drug from Dogma Therapeutics

AstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that have to be delivered via a

Novartis strikes landmark deal with NHS to speed up inclisir...

Amgen pulls higher-priced Repatha to try to lift sales

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

TMC inches closer to inclisiran approval with long-term safe...

The Medicines Company (TMC) has bet the proverbial farm on cholesterol-lowering candidate inclisiran and is celebrating new safety data that raises the chances of approval when pivotal tria

Merck axes cholesterol drug despite phase 3 success

Merck & Co has said it will not file anacetrapib with regulators